Treatment Of Adult Patients With Endocrine Resistant Pik3ca Mutated Hr Positive Her2 Negative Locally Advanced Or Metastatic Breast Cancer As Detected By An Fda Approved Test Following Recurrence On Or After Completing Adjuvant Endocrine Therapy In Combination With Inavolisib And Fulvestrant — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for treatment of adult patients with endocrine resistant pik3ca mutated hr positive her2 negative locally advanced or metastatic breast cancer as detected by an fda approved test following recurrence on or after completing adjuvant endocrine therapy in combination with inavolisib and fulvestrant. 30 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

Originators in Treatment Of Adult Patients With Endocrine Resistant Pik3ca Mutated Hr Positive Her2 Negative Locally Advanced Or Metastatic Breast Cancer As Detected By An Fda Approved Test Following Recurrence On Or After Completing Adjuvant Endocrine Therapy In Combination With Inavolisib And Fulvestrant

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating treatment of adult patients with endocrine resistant pik3ca mutated hr positive her2 negative locally advanced or metastatic breast cancer as detected by an fda approved test following recurrence on or after completing adjuvant endocrine therapy in combination with inavolisib and fulvestrant. Each bar = one year. Y-axis scaled to peak year (12 patents).

Approved drugs ranked by patent estate

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Related

• Treatment Of Adult Patients With Endocrine Resistant Pik3ca Mutated Hr Positive Her2 Negative Locally Advanced Or Metastatic Breast Cancer As Detected By An Fda Approved Test Following Recurrence On Or After Completing Adjuvant Endocrine Therapy In Combination With Inavolisib And Fulvestrant — full disease profile
• AI Patent Landscape Report — type "treatment of adult patients with endocrine resistant pik3ca mutated hr positive her2 negative locally advanced or metastatic breast cancer as detected by an fda approved test following recurrence on or after completing adjuvant endocrine therapy in combination with inavolisib and fulvestrant" for an AI exec memo
• Company Patent Rankings
• Biosimilar Opportunity Scanner